Heledd H Griffiths1, Isobel J Morten, Nigel M Hooper. 1. University of Leeds, Proteolysis Research Group, Institute of Molecular and Cellular Biology, Faculty of Biological Sciences and Leeds Institute of Genetics, Health and Therapeutics, Leeds LS2 9JT, UK.
Abstract
BACKGROUND: The amyloid beta (Abeta) peptide is critical to the development of Alzheimer's disease (AD), the major neurodegenerative disease of the elderly for which there is currently no cure. OBJECTIVE: To review the literature on emerging treatments and potential therapeutic strategies for AD. METHODS: Available published literature and information from pharmaceutical companies was utilised. RESULTS/ CONCLUSION: Several of the current treatments to combat AD are aimed at inhibiting the production, blocking the oligomerisation/aggregation or enhancing the degradation of Abeta. In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.
BACKGROUND: The amyloid beta (Abeta) peptide is critical to the development of Alzheimer's disease (AD), the major neurodegenerative disease of the elderly for which there is currently no cure. OBJECTIVE: To review the literature on emerging treatments and potential therapeutic strategies for AD. METHODS: Available published literature and information from pharmaceutical companies was utilised. RESULTS/ CONCLUSION: Several of the current treatments to combat AD are aimed at inhibiting the production, blocking the oligomerisation/aggregation or enhancing the degradation of Abeta. In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.
Authors: Mark P Burns; Lihua Zhang; G William Rebeck; Henry W Querfurth; Charbel E-H Moussa Journal: Hum Mol Genet Date: 2009-05-29 Impact factor: 6.150
Authors: Barbara Kramarz; Rachael P Huntley; Milagros Rodríguez-López; Paola Roncaglia; Shirin C C Saverimuttu; Helen Parkinson; Rina Bandopadhyay; Maria-Jesus Martin; Sandra Orchard; Nigel M Hooper; David Brough; Ruth C Lovering Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472